Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

28.7K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
28.7K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

6.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
6.4K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

4.1K
4.1K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

3.5K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report.

Journal of human immunity·2026
Same author

Working So Hard: Double-Stranded RNAs That Can Perform Both Gene Activation and Gene Silencing.

Chembiochem : a European journal of chemical biology·2026
Same author

Response to "Defining durability in SCD gene therapy".

Blood advances·2026
Same author

Mesenchymal stem cell-mediated delivery boosts the efficacy of suicide gene therapy based on retroviral replicating vectors in peritoneally disseminated cancer.

Cancer gene therapy·2026
Same author

Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in Sickle Cell Disease.

Blood·2026
Same author

Non-lytic viral immunotherapy induces long-term glioblastoma survival and tumor-specific immunity without eliciting an antiviral response.

Nature communications·2026
Same journal

Inhibition of inflammation and senescence with azole compound C7 enables expansion of hematopoietic stem and progenitor cells.

Stem cells translational medicine·2026
Same journal

The role of endothelial colony forming cells in the treatment of limb ischaemia: challenges in clinical translation.

Stem cells translational medicine·2026
Same journal

Addressing bioenergetic deficits and restoring mitochondrial health in transplanted islets using mesenchymal stem cells.

Stem cells translational medicine·2026
Same journal

HO-1-modified umbilical cord MSCs alleviate pulmonary arterial hypertension by reducing inflammation and endothelial dysfunction.

Stem cells translational medicine·2026
Same journal

Co-culturing hiPSC-cardiomyocytes and cardiac fibroblasts enhances engineered heart tissue structure and function.

Stem cells translational medicine·2026
Same journal

The mitochondria-targeting compound PTC299 enhances megakaryocyte and platelet production.

Stem cells translational medicine·2026
See all related articles

Related Experiment Video

Updated: Apr 18, 2026

Integration Free Derivation of Human Induced Pluripotent Stem Cells Using Laminin 521 Matrix
10:48

Integration Free Derivation of Human Induced Pluripotent Stem Cells Using Laminin 521 Matrix

Published on: July 7, 2017

9.3K

Putative immunogenicity expression profiling using human pluripotent stem cells and derivatives.

Jason P Awe1, Eric H Gschweng1, Agustin Vega-Crespo1

  • 1Department of Molecular and Medical Pharmacology, Department of Microbiology, Immunology, and Molecular Genetics, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, Department of Pediatrics, Mattel Children's Hospital, Jonsson Comprehensive Cancer Center, and Department of Medicine, UCLA School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

Stem Cells Translational Medicine
|January 11, 2015
PubMed
Summary
This summary is machine-generated.

Human induced pluripotent stem cells (hiPSCs) may offer immune-matched cell therapies. This study found that mouse immunogenicity genes ZG16 and HORMAD1 are not relevant in human cells, suggesting hiPSCs are safe for transplantation.

Keywords:
HORMAD1Human embryonic stem cellHuman induced pluripotent stem cellImmunogenicityPeripheral blood mononuclear cellsZG16

More Related Videos

Derivation and Characterization of a Transgene-free Human Induced Pluripotent Stem Cell Line and Conversion into Defined Clinical-grade Conditions
10:48

Derivation and Characterization of a Transgene-free Human Induced Pluripotent Stem Cell Line and Conversion into Defined Clinical-grade Conditions

Published on: November 26, 2014

8.3K
Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing
09:02

Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing

Published on: June 9, 2017

24.7K

Related Experiment Videos

Last Updated: Apr 18, 2026

Integration Free Derivation of Human Induced Pluripotent Stem Cells Using Laminin 521 Matrix
10:48

Integration Free Derivation of Human Induced Pluripotent Stem Cells Using Laminin 521 Matrix

Published on: July 7, 2017

9.3K
Derivation and Characterization of a Transgene-free Human Induced Pluripotent Stem Cell Line and Conversion into Defined Clinical-grade Conditions
10:48

Derivation and Characterization of a Transgene-free Human Induced Pluripotent Stem Cell Line and Conversion into Defined Clinical-grade Conditions

Published on: November 26, 2014

8.3K
Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing
09:02

Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing

Published on: June 9, 2017

24.7K

Area of Science:

  • Stem cell biology
  • Immunology
  • Regenerative medicine

Background:

  • Autologous human induced pluripotent stem cells (hiPSCs) are promising for cell therapeutics due to their potential to avoid immune rejection.
  • Previous studies in mice suggested that syngeneic iPSCs could elicit an immune response, creating controversy regarding the safety of hiPSC-based therapies.
  • A thorough investigation into potential acute immune responses associated with hiPSCs and their derivatives has been lacking.

Purpose of the Study:

  • To investigate the potential immunogenicity of human induced pluripotent stem cells (hiPSCs) and their derivatives.
  • To assess the relevance of mouse immunogenicity genes (ZG16 and HORMAD1) in a human context.
  • To determine if hiPSC-derived cells trigger an immune response in humans.

Main Methods:

  • Correlative gene expression analysis of human homologous genes (ZG16 and HORMAD1) in human pluripotent stem cells and their derivatives.
  • Assessing ZG16 expression levels across various human embryonic stem cell and hiPSC-derived cell types.
  • Evaluating the immunogenic potential of ectopic ZG16 expression in antigen-presenting cells using a peripheral blood mononuclear cell coculture assay.

Main Results:

  • ZG16 gene expression was found to be heterogeneous across different human embryonic stem cell and hiPSC-derived cell types.
  • Ectopic expression of ZG16 in antigen-presenting cells did not induce a detectable immune response in peripheral blood mononuclear cell coculture assays.
  • The two previously identified mouse immunogenicity genes, ZG16 and HORMAD1, do not appear to be relevant in the context of human stem cell immunogenicity.

Conclusions:

  • The investigated mouse immunogenicity genes (ZG16 and HORMAD1) are not relevant for assessing the immunogenicity of human induced pluripotent stem cells (hiPSCs).
  • Human induced pluripotent stem cells and their derivatives are unlikely to elicit an acute immune response based on these specific gene markers.
  • These findings support the potential of autologous hiPSCs for safe and effective cellular therapeutics without immune complications.